Postoperative pain is a major concern for patients after cardiovascular surgery.
With an increasing emphasis on improving perioperative care arising from evidence-based
protocols such as Enhanced Recovery After Surgery (ERAS), reducing postoperative pain not
only increases patient satisfaction, but also decreases postoperative complications and
improves outcomes. Reduced postoperative pain also decreases rates of pneumonia and time
on mechanical ventilation, in the ICU, or in the hospital. Importantly, decreasing
postoperative pain can also reduce high dose opioid usage, the established method of
managing postoperative pain, thereby decreasing rates of nausea/vomiting, intubation
time, and mortality. Methods of reducing postoperative pain, such as neuraxial anesthesia
and deep plexus blocks, are associated with an increased risk of epidural hematoma; an
alternate solution, therefore, is using fascial plane blocks.
Since 2018, our institution is one of very few that uses pre-operative fascial plane
blocks for cardiac surgery patients, implementing bilateral plane blocks for the
sternotomy approach and unilateral plane blocks for the right mini-thoracotomy approach.
Results from these blocks have been quite favorable but not yet validated.
A study in which subjects are randomized to not receive an ESP block preoperatively would
raise concerns regarding equipoise. Therefore, this study is designed to better
understand the overall effects of these blocks by comparing FDA approved medications,
Exparel (current practice at RWJUH) and Marcaine. Marcaine (0.25% bupivacaine HCl) has an
onset of action on the order of seconds and generally within one minute from the time of
injection, and an effect duration of roughly seven hours. Exparel is a commercially
available extended-release formulation of liposomal bupivacaine, which extends the effect
duration to an upward of 72 hours from the time of injection with similarly immediate
onset of action. Several studies have compared local injections of Marcaine (plain
bupivacaine) with Exparel (liposomal bupivacaine) in the setting of inguinal hernia
repair, knee arthroplasty, breast augmentation, and hemorrhoidectomy, with results
favoring the use of liposomal bupivacaine based on improvements in subjective pain at the
initial postoperative pain assessment.(6) Clinical trials are currently underway,
investigating the effect of liposomal bupivacaine for local anesthesia and compared with
epidural anesthesia in thoracoscopic surgery. In a recent clinical trial published in the
Journal of the American Medical Association (JAMA), patients undergoing cardiothoracic or
vascular surgery subjected to truncal incisions did not demonstrate a significant benefit
with respect to pain control or adjunctive opioid usage when treated with liposomal
bupivacaine over plain bupivacaine via local injection. Still, a gap in the literature
exists with respect to the use of liposomal bupivacaine versus plain bupivacaine for
erector spinae plane block in the setting of sternotomy. The aim of this prospective
study is to determine the impact of preoperative fascial plane blocks with Exparel
compared to Marcaine on outcomes following cardiac procedures.